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Acute renal dysfunction (ARD) is a common complication in renal transplant recipients. Multiple factors contribute to
ARD development, including acute rejection and microbial infections. Many viral infections after kidney transplantation
result from reactivation of “latent” viruses in the host or from the graft, such as the human Polyomavirus BK (BKV). We
report the case of a 39 year-old recipient of a 2nd kidney graft who experienced BKV reactivation after a second
episode of acute humoral rejection. A 10-day treatment with the quinolone antibiotic ciprofloxacin was administered
with an increase of immunosuppressive therapy despite the active BKV replication. Real Time PCR analysis performed
after treatment with ciprofloxacin, unexpectedly showed clearance of BK viremia and regression of BK viruria. During
the follow-up, BK viremia persisted undetectable while viruria decreased further and disappeared after 3 months.
BKV non-coding control region sequence analysis from all positive samples always showed the presence of archetypal
sequences, with two single-nucleotide substitutions and one nucleotide deletion that, interestingly, were all
representative of the subtype/subgroup I/b-1 we identified by the viral protein 1 sequencing analysis.
We report the potential effect of the quinolone antibiotic ciprofloxacin in the decrease of the BKV load in both blood
and urine.
Keywords: Polyomavirus BK infection, Fluoroquinolones, Ciprofloxacin, Renal transplant, Acute renal dysfunction,
Non-coding control region, Viral protein 1Background
Acute renal dysfunction (ARD) is a common complication
in renal transplant recipients. Many different causes may
lead to ARD such as acute rejection and microbial infec-
tions [1]. Most viral infections after renal transplantation
result from reactivation of “latent” viruses in the host or
from the graft, such as the human Polyomavirus BK (BKV)
[2]. Multiple factors contribute to viral activation after
transplantation, including immunosuppression, graft rejec-
tion therapy, inflammation and tissue injury [2]. Current
antirejection therapy, based mainly on tacrolimus (Tac) and
mycophenolic acid (MMF), has markedly decreased the
incidence of acute rejection at the expenses of an increase
of post-transplant BKV infections.* Correspondence: annapaola.mitter@uniroma1.it
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reproduction in any medium, provided the orBKV has been identified as an important emerging cause
of ARD, causing BKV nephropathy (BKVN) characterized
by interstitial nephritis and/or urinary tract stenosis [3,4].
BKV nephropathy is an important complication after renal
transplantation, affecting 1–10% of recipients and causing
graft loss in approximately 50% of cases [5]. Immunosup-
pressive therapy and treatment for acute rejection are con-
sidered primary risk factors for BKVN [6-8]. Other factors
associated with BKVN include donor and recipient charac-
teristics, human leukocyte antigens (HLA) mismatching,
ureteral stents, leukopenia, viral (co-)infections.
Limited therapeutic options are available against BKV
and the mainstay of treatment in patients with BK viremia
is reduction of immunosuppression [4,9-14]. This ap-
proach must be undertaken with caution because drug
minimization or withdrawal strategies in immunosuppres-
sion can lead to acute rejection [15].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to prevent and manage BKV infection remains a priority
particularly in transplant recipients with recurrent episodes
of rejection as in highly sensitized patients.
Despite the lack of targeted antiviral intervention, a
few agents have shown some anti-BKV activity, including
cidofovir, leflunomide, intravenous immune globulins
[16-18]. A number of in vitro and in vivo studies have
demonstrated that fluoroquinolones are capable of
inhibiting the helicase activity of BKV large T antigen
(TAg) protein, which seems to be crucial for separation
of the double-stranded DNA genome during replication
[19-23]. However it is difficult to distinguish the specific
effects of fluoroquinolones on BKV replication from those
of a concurrent reduction of immunosuppression, which
is recommended in these cases [24,25].
In this report we describe the case of a highly sensi-
tized kidney re-transplant patient who needed an overall
increase of immunosuppression, due to acute rejection,
in course of ARD associated to BKV reactivation.
Case presentation
A 39 year-old man developed two episodes of ARD 6 years
after the second kidney transplant. He had a first kidney
graft from his mother in 1993, which failed due to primary
non-function. He continued renal replacement therapy and
the allograft was not removed.
In 2004 he received the second kidney graft from a
deceased donor. The DR1 HLA class II antigen was in
common with the first kidney. Donor Specific Antibodies
(DSA) before his second transplant were not detectable and
the cross-match was negative as well. He received induction
therapy with basiliximab at standard dosage and mainten-
ance triple therapy with Tac (trough levels: 4–8 ng/mL),
MMF and steroids. Serum creatinine remained stable for
3 years, with a range of 1.5-2 mg/dL.
In December 2007 he experienced one first episode of
ARD, defined by an increase of serum creatinine above
25% of the baseline (3.6 mg/dL) and fever. BKV DNA
was tested with Real-Time PCR (Q-PCR) in blood and
urine and both samples resulted negative. The cross-match
was mildly positive at <30%. He was empirically treated
with steroid pulses and an overall increase in immunosup-
pression with a modest improvement of renal function.
In April 2010 he developed a second episode of ARD,
characterized by a further acute raise in serum cre-
atinine to 7.2 mg/dL, reduction of diuresis, diffuse
edematous state, proteinuria, metabolic acidosis and
hypertension. At the same time BKV DNA, previously
negative, converted both in blood and urine samples.
BKV DNA loads were 7.2x103 copies/mL and 5.6x104
copies/mL, respectively (Figure 1); moreover B-cell cross-
match (B-FXM) resulted positive (50%) and DSA against
DR1 became detectable.The transplanted kidney showed normal vascular
patterns at Doppler ultrasound. A cystogram showed
urethral stenosis and reflux at the uretero-vesical junction
thus urinary tract infection prophylaxis was started using
ciprofloxacin (250 mg twice daily for ten days), adjusted
for glomerular filtration rate.
The renal biopsy showed acute humoral rejection
Banff type I [26] with no signs of BKVN (Figure 2). BKV
detection by Q-PCR in renal tissue was negative. Therefore,
in spite of active BKV replication, the immunosuppression
was increased. The target Tac trough levels were set to
9 ng/mL and high dose steroid pulses and rituximab
(375 mg/m2 weekly for 4 cycles) were given. Moreover he
underwent 13 sessions of plasma-apheresis and 5 sessions
of photo-apheresis.
BKV replication in blood and urine was strictly mon-
itored. Real-Time PCR analysis performed in May, after
treatment with ciprofloxacin, unexpectedly showed clear-
ance of BK viremia and regression to 1x104 copies/mL of
viruria, despite the increase in immunosuppression. After a
temporary mild improvement serum creatinine deteriorated
further and was 5 mg/dL after 1 month. B-cell cross-match
decreased but persisted positive (30%).
During the follow-up, BK viremia persisted undetectable
while viruria further decreased (2.3x103 copies/mL) until
disappearing after 3 months. Unfortunately renal function
did not improve, with hindsight probably due to the poor
responsiveness of acute humoral rejection in the presence
of irreversible chronic renal lesions. The patient started
renal replacement therapy 5 months later.
Retrospectively we performed the molecular charac-
terization of the BKV viral protein 1 (VP1) and non-
coding control region (NCCR) on the urine and blood
samples which were positive for viral DNA during the
follow-up. Both regions, amplified by specific nested PCR
and sequenced using a dedicated facility, were analysed to
classify the BKV strains obtained into the corresponding
subtype/subgroup, examining the single nucleotide poly-
morphisms within the VP1 region, and to investigate the
presence of possible rearrangements within the NCCR.
All BKV strains isolated in both urine and blood belonged
to the archetype strains (WW), with VP1 genotype defined
as subtype I/subgroup b-1.
Discussion
We have reported the case of a highly sensitized re-
transplant patient who developed a second ARD episode
associated to BKV reactivation. The differential diagnosis
between acute rejection and BKVN was crucial as these
conditions require opposite therapeutic strategies [27]. Our
patient underwent a renal biopsy which showed acute
humoral rejection without signs of BKVN and Q-PCR ana-
lysis did not detect the virus in kidney cells. Consequently
the moderate BKV load found in urinary and circulatory
Figure 1 Time course of clinical events and laboratory examinations.
Figure 2 Histopathological examination by Periodic Acid Schiff
reaction, x200. Glomeruli are characterized by widespread, intense
mononuclear infiltration, moderate increase of the matrix and focal
pericapsular fibrosis. Arteries show intense intimal fibrosis and
fragmentation of the internal elastic lamina, arterioles are
characterized by intense intimal hyalinosis. Edema and inflammatory
infiltration of lymphocytes without plasmacells are present in the
interstitium. Peritubular capillaries are markedly dilated with
leucocytes margination. Epithelium of the proximal tubules occurs
frequently flattened; into the lumen of the distal tubules, sometimes
dilated, are contained hyaline casts. No nuclear inclusions are
detected in the tubular epithelium. Search for C4d, evaluated by
immunohistochemistry on tissue sections fixed, was positive (+ +)
on the walls of peritubular capillaries.
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stricted to urothelial cells, as supported by the pres-
ence of urethral stenosis with active reflux of the
uretero-vesical junction. Moreover BKVN can be focal
in distribution, therefore kidney biopsy could fail to
detect viral tissue replication [28].
Despite the active BKV replication the diagnosis of acute
rejection led to an increase of the anti-rejection therapy.
Antiviral drugs to treat BKV were not commenced due
to their nephrotoxicity [29], though BKV replication rate
was strictly monitored in blood and urine. An unexpected
reduction in BKV replication was noted. Plasma-apheresis
played no role as it started after BK viruria regression to
1x104 copies/mL. It was then hypothesized that fluoro-
quinolone ciprofloxacin, used as from the centre’s protocol
for urinary tract infection prophylaxis after a cystogram,
could have played a role in reducing viral replication.
It is known that quinolones display anti-BKV properties
through inhibition of polyomavirus associated TAg helicase
activity [19,20,24]. Fluoroquinolones not only reduce BKV
DNA replication and the associated protein expression
(for example TAg, viral capsid proteins and agnoprotein)
but also lower the cell release of viral progeny by more
than 90% [19]. Recently this class of antibiotics has been
shown to have effects on BK viremia and/or viruria after
transplantation; however all studies described the impact
of prophylactic administration of these antibiotics on
BKV replication or their association with simultaneous
immunosuppression reduction [15,16,22,24,25,30]. In such
cases it is difficult to know whether the reduction of BKV
replication is due to a direct effect of fluoroquinolones or
to the reduction of immunosuppression.
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ciprofloxacin, unexpectedly showed a regression in BK
viruria and the clearance of viremia. The decreasing trend
in BKV load in urine was observed until July 2010 when
BKV DNA disappeared. During the entire follow-up for BK
viruria and viremia serum creatinine had a temporary slight
improvement and Tac trough levels were maintained in
therapeutic range (Figure 1). Unfortunately renal function
did not improve and patient started renal replacement ther-
apy 5 months later. We exclude a ciprofloxacin nephrotoxic
role in renal function worsening because the renal biopsy
showed the presence of irreversible chronic renal lesions
not related to the drug toxicity. Moreover the drug dosage
was adjusted for glomerular filtration rate.
To our knowledge, none of the studies reported in
literature concerning the effects of fluoroquinolones
on BKV replication has evaluated the presence of pos-
sible rearrangements within the BKV NCCR, a region
of approximately 400 bp containing the origin of DNA
replication (Ori) and the promoter/enhancer elements
involved in transcriptional regulation of both the early
and the late viral genes. BKV variants with rearranged
NCCR have been identified in various studies including
kidney transplant recipients [31]. Alignment of all NCCR
sequences, detected from each BKV-positive clinical sam-
ple of our patient, with the prototypic NCCR sequence
proposed by Yogo and colleagues [32], revealed that all
specimens were defined by the presence of two nucleotide
substitutions and a single nucleotide deletion occurring atFigure 3 Alignment of BKV prototypic NCCR sequence with archetypa
(proto) NCCR is shown at the top of the figure and the BKV archetype WW
belonged to subtype I subgroup b-1, we found in urine and blood specim
nucleotides indicated by hyphens and the deletion identified by a triangle
[35] are indicated below the prototypic NCCR sequence.nucleotide positions 52, 65 and 254, respectively (Figure 3).
All these point mutations were typical of the consensus
NCCR sequence identified for the BKV subtype I subgroup
b-1 [32], which is widespread throughout the world [33].
The subgroup I/b-1 was also identified by molecular ana-
lysis of the BKV VP1 coding sequence between nucleotides
1744 and 1812 (amino acids 61 to 83) [34], which allows to
define the BKV genotypes and their different distribution in
the human populations.
Although NCCR is the most hyper-variable region of
Polyomavirus genome, it still remains unclear what
molecular mechanisms operates to generate rearranged
NCCRs [36]. It has been suggested that recombination
occurs between two newly synthesized daughter segments
of a replicating DNA molecule at non-homologous points
[37]. BKV genome is replicated bi-directionally starting
from the Ori and the separation of daughter molecules is
a slow step involving replicative intermediates with at least
three chains, two daughter strands and the unreplicated
parental DNA [38]. At the initial stage of replication, the
three Ori sequences are in very close proximity, and
this may facilitate major rearrangements through self-
recombination. The lack of rearrangements within the
non-coding control region of BK virus in both urinary
and circulatory compartments of our patient may have
depended on the mechanism of action of fluoroquinolones.
As already mentioned above, these drugs represent a potent
group of antibiotics able to inhibit BKV DNA replication by
interfering with the helicase function of its TAg protein,l WW NCCR sequences detected in our patient. The prototypic
strain NCCR consensus sequence (GenBank accession no. AB211371),
ens is shown below in relation to the prototypic NCCR, with similar
. Blocks (O, P, Q, R and S) commonly used to denote archetypal NCCRs
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coordinates its bidirectional replication in the presence of
host DNA polymerase and topoisomerase II. It has been
speculated that quinolones may prevent the TAg helicase
activity by disrupting TAg-DNA interaction, due to a direct
binding of these drugs to the DNA that TAg uses as
substrate, or, alternatively, by converting the TAg-DNA
complex into a frozen DNA-quinolone-TAg intermediate
[20]. Nevertheless, whatever the exact mechanism of inhib-
ition of TAg functions, the viral DNA cannot be replicated
and consequently it cannot undergo rearrangements.
Moreover, whether deletions and duplications of certain
NCCR regions were associated with replicative advantage
in an immunocompromised host, these alterations could
be detected more frequently since they would be positive
selected, but this did not happen in our case.
Conclusions
This is the first report showing a progressive reduction in
BKV replication in a patient who underwent ciprofloxacin
treatment concurrently with an increase of immunosup-
pressive therapy.
The quinolone antibiotic ciprofloxacin administration
could have played an active role in reducing BKV repli-
cation and eradicated the BKV load in both urinary and
circulatory compartments.
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